Huperzine A - Shandong Luye Pharmaceuticals
Latest Information Update: 17 Jun 2015
At a glance
- Originator Shandong Luye Pharmaceutical
- Class Alkaloids; Neuroprotectants; Nootropics; Sesquiterpenes
- Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein inhibitors; Antioxidants; NMDA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 17 Jun 2015 No recent reports on development identified - Phase-II/III for Alzheimer's disease in China (PO)